Head and Neck Squamous Cell Carcinoma (HNSCC)

Inquiry

Head and neck squamous cell carcinoma (HNSCC) is a highly heterogeneous and difficult-to-treat malignancy that severely affects swallowing, speech, and quality of life. Alfa Cytology is a global leader in cancer research. With our extensive experience and advanced platforms, our talented scientists provide one-stop solutions for HNSCC animal model development, efficacy evaluation, oral/pharyngeal orthotopic model validation, cervical lymph node metastasis evaluation, radiotherapy combination studies, postoperative relapse studies, tumor immunology testing, target expression validation, pathology testing, molecular mechanism testing, and PK/PD, based on client candidate drugs, HPV status, anatomical site, target expression, radiotherapy combination strategy, local delivery route, immune system requirements, lymph node metastasis risk, and R&D stages. We also provides zebrafish experimental services and cell-based experimental services, covering diverse research needs from in vitro to in vivo and from high-throughput screening to mechanism validation.

Introduction to Head and Neck Squamous Cell Carcinoma (HNSCC)

HNSCC is a malignant tumor originating from the mucosal epithelium of the oral cavity, oropharynx, hypopharynx, and larynx, and is one of the most common malignancies worldwide. HNSCC is highly heterogeneous, with significant differences in HPV status, anatomical site, driver gene, target expression, local microenvironment, lymphatic drainage, and radiotherapy response.Clinically, HNSCC is commonly classified into HPV-positive and HPV-negative categories based on HPV status. HPV-positive oropharyngeal cancer has a relatively better prognosis and responds better to radiotherapy and immunotherapy; HPV-negative HNSCC is more often associated with smoking and alcohol consumption, has a poorer prognosis, and relies more on surgery, radiotherapy, chemotherapy, and EGFR-targeted therapy. Different anatomical sites (oral cavity, oropharynx, hypopharynx, larynx) also differ markedly in local structure, blood supply, lymphatic drainage, and radiotherapy response. Common metastatic routes in HNSCC include cervical lymph node metastasis and distant lung metastasis. Among these, cervical lymph node metastasis is an important basis for clinical staging and treatment decisions, and is a key scenario requiring dedicated modeling in animal studies. The HNSCC immune microenvironment, tumor-infiltrating lymphocytes, PD-L1 expression, and cytokine networks play important roles in treatment response and resistance. Therefore, HNSCC animal studies need to be differentially designed based on HPV status, anatomical site, target expression, radiotherapy combination strategy, immune system requirements, and administration route, in order to better support candidate screening, efficacy evaluation, and clinical translation assessment.

Fig. 1 HNSCC anatomical sites. Fig. 1 Anatomical sites of HNSCC development. (Johnson DE, et al.; 2020)

Our Services

Alfa Cytology has established a comprehensive solution platform for head and neck squamous cell carcinoma animal experimental research, built around HPV-negative HNSCC, HPV-positive oropharyngeal cancer, EGFR/MET/TGF-β targeting, radiotherapy sensitization, oral/oropharyngeal/hypopharyngeal/laryngeal orthotopic microenvironment, cervical lymph node metastasis, lung metastasis, immunotherapy, humanized immunotherapy, and postoperative relapse/MRD scenarios. Leveraging this integrated platform, we provide end-to-end services covering the full HNSCC drug development workflow.

Preclinical Efficacy Studies

Head and neck squamous cell carcinoma drug development requires model selection based on HPV status, anatomical site, target expression, radiotherapy combination strategy, local delivery route, immune requirements, and lymph node metastasis risk. Alfa Cytology provides integrated animal study solutions, from cell line selection to model validation, for EGFR/MET/TGF-β targeted agents, radiotherapy sensitization, chemotherapy, ADCs, bispecifics, TCEs, CAR-T/NK, PD-1/PD-L1, STING, local delivery, and postoperative relapse/MRD programs.

In Vitro and In Vivo Layered Validation

Animal studies can address whether a candidate inhibits tumor growth, local invasion, cervical lymph node metastasis, lung metastasis, or postoperative relapse; zebrafish platforms provide high-throughput in vivo screening covering tumor proliferation, oral/oropharyngeal orthotopic colonization, local invasion, lymph node dissemination, angiogenesis, immune co-culture, and drug toxicity; cell-based experiments validate proliferation, apoptosis, migration and invasion, EGFR/MET/TGF-β pathways, HPV E6/E7, radiosensitivity, ADC internalization, and immune killing.

Clinical Relevance Studies

When programs advance to oral/oropharyngeal/hypopharyngeal/laryngeal orthotopic microenvironment, cervical lymph node metastasis, lung metastasis, radiotherapy combination, immunotherapy, humanized immunotherapy, local delivery, or postoperative relapse/MRD stages, Alfa Cytology can further configure orthotopic models, metastasis models, syngeneic immunocompetent models (MOC1/MOC2/SCCVII), humanized immune models, or post-resection relapse models to help clients generate evidence more aligned with clinical scenarios.

HNSCC Mechanism Research

For HNSCC studies, experimental design typically needs to address HPV stratification, anatomical site, local mucosal microenvironment, lymphatic drainage, radiotherapy response, and immune microenvironment simultaneously. Alfa Cytology provides model development, dosing intervention, pathology testing, immunology testing, protein testing, and RNA testing services, covering HPV-negative HNSCC, HPV-positive oropharyngeal cancer, EGFR/MET/TGF-β pathways, radiotherapy sensitization, cervical lymph node metastasis, lung metastasis, local relapse, and MRD clearance.

Candidate Screening

Early screening typically requires rapid assessment of whether a candidate demonstrates in vivo antitumor signals. Alfa Cytology conducts TGI, RTV, PK/PD, and target evaluations using HPV status-matched subcutaneous CDX models, providing data to support dose selection, dosing frequency, and candidate prioritization.

Molecular Mechanism Studies

Depending on program needs, we offer IHC, IF, flow cytometry, ELISA, Western blot, qPCR, RNA-seq, HPV E6/E7 testing, p16, EGFR/pERK, MET, TGF-β, PD-L1, CD8/Treg, myeloid cell profiling, cytokines, human immune reconstitution rate, local tissue drug concentration, and post-radiotherapy residual margin testing.

For clients with only a candidate drug, target direction, or preliminary mechanistic hypothesis, Alfa Cytology assists in structuring cell line selection, model pathways, group design, dosing regimens, detection endpoints, terminal sample collection, and data presentation，translating R&D questions into executable animal study protocols. Our capabilities support a broad spectrum of therapeutic modalities, including but not limited to:

Supported R&D Programs

R&D Project	Cell Lines	Host System	Preferred Model	Key Endpoints
Early efficacy screening and dose exploration	FaDu, CAL-27, SCC-9, SCC-15, SCC-25, Detroit 562, UM-SCC-47, UPCI-SCC090	BALB/c nude, NOD-SCID, NSG mice	Subcutaneous CDX	TGI, RTV, terminal tumor weight, body weight, Ki67, cleaved caspase-3, EGFR, PK/PD.
HPV-negative HNSCC efficacy screening	FaDu, CAL-27, SCC-9, SCC-15, SCC-25, Detroit 562	BALB/c nude, NOD-SCID, NSG mice	HPV-negative subcutaneous CDX, orthotopic model for confirmation	TGI, EGFR, pERK, Ki67, apoptosis, CD31, RTV, PK/PD.
HPV-positive oropharyngeal cancer research	UM-SCC-47, UPCI-SCC090, 93-VU-147T; mEER and other HPV-related murine models	NOD-SCID, NSG mice; C57BL/6 immunocompetent mice	HPV-positive CDX, HPV-positive orthotopic or immune-related model for deeper evaluation	p16, HPV E6/E7, TGI, radiosensitivity, immune infiltration, survival.
EGFR targeting and radiosensitization	FaDu, CAL-27, SCC-15, SCC-25; MOC1, MOC2	BALB/c nude, NOD-SCID, NSG mice; C57BL/6 immunocompetent mice	EGFR expression-confirmed CDX, orthotopic radiotherapy model for confirmation	EGFR, pERK, TGI, post-radiotherapy residual disease, necrosis, apoptosis, local relapse.
MET / TGF-β / ADC / bispecific programs	FaDu, CAL-27, SCC series, Detroit 562 and target-positive models	BALB/c nude, NSG mice	Target-positive CDX for early screening, orthotopic or relapse model for confirmation	Target expression, target retention, TGI, ADC distribution, local invasion, PK/PD.
Oral/pharyngeal orthotopic microenvironment	FaDu-luc, CAL-27-luc, SCC-9-luc; MOC1-luc, MOC2-luc	NOD-SCID, NSG mice; C57BL/6 immunocompetent mice	Tongue, floor-of-mouth, buccal mucosa, oropharyngeal or hypopharyngeal orthotopic model	Orthotopic burden, BLI, body weight, feeding, local invasion, cervical lymph node metastasis, survival.
Radiotherapy combination / post-radiotherapy relapse	MOC1-luc, MOC2-luc; FaDu-luc, CAL-27-luc	C57BL/6 immunocompetent mice; NSG or NOD-SCID mice	Orthotopic syngeneic model preferred, with resection or post-radiotherapy relapse when needed	Post-radiotherapy burden change, residual margin, necrosis, PD-L1, CD8/Treg, time to relapse, survival.
Cervical lymph node metastasis and local relapse	MOC2-luc, MOC1-luc; FaDu-luc, CAL-27-luc	C57BL/6 immunocompetent mice; NSG or NOD-SCID mice	High-invasion orthotopic model or post-resection relapse model	Time to local relapse, cervical lymph node metastasis rate, BLI, residual lesions, lung metastasis, survival.
Experimental lung metastasis	MOC2, FaDu-luc, CAL-27-luc	C57BL/6 immunocompetent mice or NSG/NOD-SCID mice	Tail vein lung colonization model	Lung nodule count, lung weight, BLI, lung histopathology, survival.
Immune checkpoint / TME remodeling	MOC1, MOC2; SCCVII	C57BL/6 immunocompetent mice; C3H immunocompetent mice	Syngeneic subcutaneous screening, syngeneic orthotopic model for confirmation	CD8/Treg, myeloid cell profile, PD-L1, cytokines, TGI, orthotopic burden, survival.
HPV-related immunotherapy or de-escalation therapy	mEER and other HPV-related murine models; UM-SCC-47, UPCI-SCC090	C57BL/6 immunocompetent mice; NSG or humanized mice	HPV-positive syngeneic or human-stratified model	HPV antigen, p16, radiotherapy response, CD8 infiltration, immune memory, tumor burden.
TCE / CAR-T/NK / human immune-dependent therapies	FaDu, CAL-27, UM-SCC-47, UPCI-SCC090 and target-positive models	huPBMC or huHSC-reconstituted NSG/NOG mice	Humanized immune model	hCD45, hCD3, hCD8, hNK, T cell activation, cytokines, CRS/xGvHD risk.
Postoperative relapse / MRD clearance	MOC2-luc, MOC1-luc; FaDu-luc, CAL-27-luc	C57BL/6 immunocompetent mice; NSG or NOD-SCID mice	Orthotopic model with local resection or local radiotherapy followed by follow-up	Local relapse rate, time to relapse, cervical lymph node metastasis, lung metastasis, BLI, survival.

Comprehensive Test and Data Analysis Platform

For HNSCC programs focused on HPV stratification, local invasion, and cervical lymph node metastasis evaluation, we configure TGI, RTV, terminal tumor weight, BLI, orthotopic tumor burden, local invasion depth, cervical lymph node metastasis rate, lung nodule count, survival, EGFR, pERK, MET, TGF-β, p16, HPV E6/E7, CD31, PD-L1, CD8/Treg, and local tissue drug concentration, forming an integrated data chain linking local lesions, lymphatic dissemination, and immune microenvironment.

Multimodal In Vivo Imaging

IVIS Spectrum photon bioluminescence quantification for oral/oropharyngeal orthotopic tumors and cervical lymph node metastasis tracking
7.0T small-animal high-field MRI for local invasion depth and cervical lymph node scanning
micro-CT 3D reconstruction for mandibular invasion and cervical structure assessment

Pathology and IHC/IF Staining

EGFR / pERK / MET / TGF-β / p16 / HPV E6/E7 target assessment
Ki67 / Cleaved-Caspase 3 proliferation and apoptosis index
mIF multiplex immunofluorescence for in situ target and head and neck TME quantification

TME Microenvironment and Immune Profiling

Head and neck tumor TILs (CD4+ / CD8+ / Treg) and myeloid cell analysis
Post-radiotherapy immune infiltration and PD-L1 change analysis
Cytokine storm (IFN-γ / IL-6) CBA suspension array

Access Our HNSCC Model Library

HNSCC Cell Line Panel

Alfa Cytology's HNSCC cell line panel covers five key areas, including HPV stratification, anatomical site, EGFR/MET/TGF-β pathway, radiotherapy combination, and immuno-oncology, enabling cell line selection and matching based on HPV status, anatomical site, target expression, and immune system requirements.

HPV-Negative Related Cell Lines

FaDu: a hypopharyngeal and HPV-negative HNSCC model suitable for chemotherapy, radiotherapy sensitization, EGFR pathway, ADC, and local invasion research.
CAL-27: stable tumor formation, suitable for subcutaneous CDX and oral orthotopic modeling; commonly used for EGFR, radiotherapy sensitization, and cisplatin combination studies.
SCC-9, SCC-15, SCC-25: oral SCC background models suitable for oral mucosa, epithelial differentiation, EGFR, local delivery, and mechanism research.
Detroit 562: an HPV-negative HNSCC and pharyngeal-related model suitable for targeted agent screening and hypopharyngeal/pharyngeal background research.

HPV-Positive Related Cell Lines

UM-SCC-47: a commonly used HPV-positive HNSCC cell line suitable for HPV-related oropharyngeal cancer, p16, HPV antigen, and radiosensitivity research.
UPCI-SCC090: suitable for HPV-positive HNSCC stratification research, including basic efficacy, HPV status validation, and target mechanism studies.
93-VU-147T: an HPV-positive model supplement suitable for HPV status, radiosensitivity, and immune-related mechanism exploration.
mEER and other HPV-related murine models: suitable for HPV-positive related research in immunocompetent background.

Immuno-Oncology-Related Cell Lines

MOC1: immune-hot phenotype, suitable for immune checkpoint, radiotherapy combination, T cell infiltration, and immune mechanism research.
MOC2: more invasive, immune-cold, suitable for local relapse, cervical lymph node metastasis, and low immune response research.
SCCVII: a C3H background syngeneic model suitable for radiotherapy, biology, and strain supplementary validation.

Invasion and Metastasis-Related Cell Lines

CAL-27-luc, FaDu-luc: suitable for oral orthotopic, radiotherapy combination, local relapse, and visualization monitoring.
MOC2-luc: suitable for local relapse, cervical lymph node metastasis, and anti-metastasis research.
MOC2: suitable for tail vein experimental lung metastasis research.

Target Expression-Related Cell Lines

EGFR: FaDu, CAL-27, SCC-15, SCC-25.
MET / TGF-β: HPV-negative and high-invasion models.
Target expression should be re-verified in vitro, after tumor formation, and at the endpoint stage to avoid misinterpretation due to insufficient target expression.

HNSCC Animal Model Panel

Alfa Cytology provides end-to-end HNSCC animal model development services, spanning model design, cell line selection, model construction, dosing intervention, efficacy evaluation, pathology, immunology, molecular mechanism testing, and PK/PD analysis. The models below represent our core capabilities across HPV-negative HNSCC, HPV-positive oropharyngeal cancer, EGFR/MET/TGF-β targeting, and radiotherapy combination research. Each model can be customized to match your program's HPV status, anatomical site, target expression, immune requirements, and cervical lymph node metastasis risk, from early screening to clinical relevance validation.

Subcutaneous Xenograft Model (CDX)

Subcutaneous CDX models typically involve inoculating human HNSCC cells subcutaneously into immunodeficient mice, followed by randomization and dosing once tumors reach a predetermined volume.

HPV-negative cell lines: FaDu, CAL-27, SCC-9, SCC-15, SCC-25, Detroit 562
HPV-positive cell lines: UM-SCC-47, UPCI-SCC090, 93-VU-147T

Model characteristics
Subcutaneous CDX is suitable for early efficacy studies, target validation (e.g., EGFR, MET, TGF-β), dose exploration, PK/PD studies, and resistance and combination therapy research. This model cannot fully reflect the oral/oropharyngeal/hypopharyngeal/laryngeal orthotopic microenvironment, mucosal immunity, cervical lymph node metastasis, local invasion depth, swallowing impact, or post-radiotherapy residual disease.

Modeling and dosing timelines
Palpable tumor volumes suitable for enrollment are typically reached 1–3 weeks after inoculation, and stratified randomization by tumor volume is recommended. The conventional treatment observation period is usually 2–4 weeks; for special projects (resistance, sustained-release formulations, ADCs, or antibody drugs), this can be extended according to pharmacokinetic and toxicity windows. For resistance, recurrence, or sustained suppression studies, a post-treatment withdrawal observation period can be added to record tumor regrowth and regrowth rate.

Detection endpoints

Basic efficacy layer: TGI, RTV, terminal tumor weight, body weight, general condition, progression-free time, and survival

Molecular mechanism layer: Ki67, cleaved caspase-3, TUNEL, EGFR, pERK, MET, TGF-β, p16, HPV E6/E7, and DNA damage markers

PK/PD layer: Plasma drug concentration, tumor tissue concentration, target occupancy, pathway inhibition, and ADC tissue distribution

Safety layer: Body weight, complete blood count, liver and kidney function, and major organ pathology

Recommended positive controls
For HPV-negative programs, cisplatin, 5-FU, or cetuximab can be selected; for HPV-positive programs, cisplatin plus radiotherapy references can be used; for EGFR-targeted programs, cetuximab references can be selected. Specific doses should be adjusted based on model and administration route.

Orthotopic Implantation Model

Orthotopic implantation models typically involve inoculating tumor cells into the tongue, floor of mouth, buccal mucosa, oropharynx, or hypopharynx to mimic the head and neck mucosal organ microenvironment, often using luc-labeled cells for dynamic monitoring.

Oral orthotopic models: CAL-27-luc, SCC-9-luc, SCC-15-luc, HSC-3-luc, SAS-luc
Oropharyngeal/hypopharyngeal orthotopic models: FaDu-luc, MOC1-luc, MOC2-luc

Model characteristics
Suitable for oral mucosal microenvironment, local invasion, local drug delivery, radiotherapy combination, and cervical lymph node metastasis research. Orthotopic models are closer to clinical scenarios than subcutaneous models, but have lower throughput, complex procedures, and high inter-batch variability. Early screening can first use subcutaneous CDX, followed by orthotopic validation.

Modeling and dosing timelines
Orthotopic models are typically observed for 3–6 weeks, depending on the cell line, inoculation site, and tumor growth rate. Luc-labeled models can be longitudinally monitored by BLI. The treatment window is usually 2–6 weeks. Radiotherapy combination programs should be designed based on irradiation dose, fractionation scheme, and dosing sequence.

Detection endpoints

Tumor burden layer: BLI, orthotopic tumor burden, local invasion depth, swallowing and body weight changes, and survival
Local invasion layer: Mucosal infiltration, muscle invasion, cervical lymph node metastasis, and local pathology
Mucosal microenvironment layer: TILs, TAM, MDSC, cytokines, and immune infiltration
Drug exposure layer: Plasma drug concentration, local tissue drug concentration, and mucosal exposure

Recommended positive controls
For radiotherapy combination programs, cisplatin concurrent radiotherapy references can be set; for local drug delivery programs, systemic dosing controls and local dosing controls can be set up; for immunotherapy programs, anti-PD-1 or anti-PD-L1 references can be set.

Post-Resection Relapse and Cervical Lymph Node Metastasis Model

Post-resection relapse and cervical lymph node metastasis models typically use MOC2-luc, MOC1-luc, FaDu-luc, or CAL-27-luc orthotopic models as the base. Once local lesions reach a predetermined burden, partial resection, local resection, or local radiotherapy is performed, followed by continuous observation of local relapse, cervical lymph node metastasis, and lung metastasis.

Model characteristics
If the focus is local relapse, low immune response, and cervical lymph node metastasis, MOC2-luc is preferred; if the focus is immunotherapy combined with radiotherapy, MOC1-luc is more suitable; if human validation is required, FaDu-luc or CAL-27-luc can be selected.

Modeling and dosing timelines
Establish orthotopic tumor burden first, then perform local resection or radiotherapy, followed by withdrawal or maintenance therapy, with continuous observation of time to relapse, relapse rate, and distant metastasis. The observation period is typically 6–10 weeks or longer.

Detection endpoints

Time to local relapse, relapse rate, cervical lymph node metastasis rate, lung metastatic nodule count, BLI/IVIS, tissue necrosis, residual margin, immune infiltration profile, and survival.

Recommended positive controls
Cisplatin combined with radiotherapy can serve as a basic reference; for EGFR-related programs, cetuximab can be set; for immunotherapy programs, anti-PD-1 antibody, anti-PD-L1 antibody, or immune combination regimens can be set.

Experimental Lung Metastasis Model

Experimental lung metastasis models typically involve tail vein injection of MOC2, FaDu-luc, or CAL-27-luc cells, suitable for observing lung colonization after circulation and the latter half of distant dissemination.

Model characteristics
Experimental lung metastasis models have shorter cycles and concentrated readouts, but cannot replace local relapse and cervical lymph node metastasis models. In HNSCC, they are typically used as a supplementary platform.

Modeling and dosing timelines
After tail vein injection, the modeling window is typically 1–4 weeks, and the observation period is determined by cell line and inoculation amount.

Detection endpoints

Lung nodule count, lung weight, BLI/IVIS, lung tissue HE, metastatic area, Ki67, apoptosis, and survival.

Recommended positive controls
Cisplatin, EGFR-targeted agents, immunotherapy combinations, or anti-metastasis strategy references can be set according to program mechanism.

HPV-Positive Related Metastasis Model

HPV-positive related metastasis models can select HPV-positive human models or HPV-related murine models based on research objectives, combined with orthotopic or metastasis design to observe local control, immune response, and distant dissemination.

Model characteristics
The core issues in HPV-positive HNSCC are typically not simple lung colonization, but local control, radiosensitivity, and immune response differences. Therefore, model design should be independently developed around HPV status.

Modeling and dosing timelines
The modeling window and observation period are determined by the selected HPV-positive human model or HPV-related murine model, with dosing intervention combined with orthotopic or metastasis design.

Detection endpoints

HPV/p16, HPV E6/E7, local relapse, lung metastasis, radiotherapy response, CD8 infiltration, and survival.

Recommended positive controls
Cisplatin combined with radiotherapy, HPV antigen immunity, or immune checkpoint references can be set according to program mechanism.

Syngeneic Subcutaneous Model

Syngeneic subcutaneous models typically involve inoculating MOC1 and MOC2 into C57BL/6 mice subcutaneously, with SCCVII as a supplementary model in C3H mice. Randomization is performed once tumors reach approximately 50–100 mm³.

Model characteristics
Suitable for immune checkpoint, STING, radiotherapy combination, cytokines, combination therapy screening, and early TME evaluation.

Modeling and dosing timelines
Randomization is performed once tumors reach approximately 50–100 mm³. The conventional treatment observation period is usually 2–4 weeks; immunotherapy or radiotherapy combination programs can be extended according to mechanism and tolerance.

Detection endpoints

Tumor volume, TGI, survival, body weight, flow cytometry immune profiling, CD8/Treg, myeloid cell profile, PD-L1, cytokines, and IHC/IF.

Recommended positive controls
Anti-PD-1 antibody, anti-PD-L1 antibody, anti-CTLA-4 antibody, STING agonists, and radiotherapy combination can serve as immunotherapy references. Antibody doses typically start at 100–200 μg/mouse intraperitoneally, twice weekly or once every 3 days.

Syngeneic Orthotopic Model

Syngeneic orthotopic models typically involve inoculating MOC1-luc and MOC2-luc into the tongue, floor of mouth, or buccal mucosa of C57BL/6 mice, establishing an orthotopic model that combines the head and neck local microenvironment with an intact immune system.

Model characteristics
Suitable for immunotherapy, radiotherapy combination, local invasion, cervical lymph node metastasis, postoperative relapse, and post-radiotherapy relapse research. MOC1 is more suitable for immunotherapy and radiotherapy combination, while MOC2 is more suitable for invasion, low immune response, and metastasis research.

Modeling and dosing timelines
Orthotopic models are typically observed for 3–6 weeks, and luc-labeled models can be longitudinally monitored by BLI/IVIS. The treatment window is usually 2–6 weeks. Radiotherapy combination programs should be designed based on irradiation dose, fractionation scheme, and dosing sequence.

Detection endpoints

Orthotopic tumor burden, BLI/IVIS, body weight, feeding status, cervical lymph node metastasis, lung metastasis, survival, CD8/Treg, MDSC, macrophages, PD-L1, MHC-I, cytokines, and spatial immune analysis.

Recommended positive controls
Radiotherapy combination studies should prioritize MOC1 or MOC2 orthotopic models. MOC1 is suitable for immune checkpoint combined with radiotherapy; MOC2 is suitable for low-response, local relapse, and lymphatic metastasis scenarios. Radiotherapy combination studies should not only look at short-term tumor shrinkage, but should include time to local relapse, lymph node metastasis rate, survival, residual margin, necrosis area, and immune infiltration changes.

huPBMC Combined with Human HNSCC Model

The huPBMC model establishes a short-term human immune effector environment by infusing human peripheral blood mononuclear cells into immunodeficient mice, combined with human HNSCC cells. Commonly used cells include FaDu, CAL-27, UM-SCC-47, and UPCI-SCC090.

Model characteristics
Suitable for TCE, bispecific antibodies, CAR-T/NK, human cytokines, human PD-1/PD-L1, and ADCs highly dependent on human immune effects. This model is relatively rapid to establish and suitable for short-cycle validation, but carries xGvHD risk, and primary endpoints should be completed within a controllable window.

Modeling and dosing timelines
A short-term human immune effector environment is established by infusing human peripheral blood mononuclear cells; modeling is relatively rapid, and primary endpoints should be completed within a controllable window.

Detection endpoints

hCD45, hCD3, hCD4, hCD8, hNK, T cell activation, tumor infiltration, IFN-γ, TNF-α, IL-6, Granzyme B, tumor burden, body weight, CRS, and xGvHD risk markers.

Recommended positive controls
Anti-human PD-1 antibody, anti-human PD-L1 antibody, or anti-human CTLA-4 antibody can serve as mechanistic references, with doses determined by model window and human immune reconstitution status. TCE, CAR-T, or CAR-NK programs should include target-positive, target-low/negative, effector cell controls, and empty vector/irrelevant TCE controls. Cell therapy doses are often designed on the order of 10⁶–10⁷ cells/mouse, determined by the cell product and safety window.

huHSC Combined with Human HNSCC Model

The huHSC model reconstructs a relatively long-term human immune system via human hematopoietic stem cells, suitable for long-cycle human immune reconstitution, complex combination strategies, and immune resistance research.

Model characteristics
Suitable for sustained immune activation, TCE, CAR-T/NK, bispecifics, human immune checkpoints, resistance research, and complex TME mechanism validation.

Modeling and dosing timelines
A relatively long-term human immune system is reconstructed via human hematopoietic stem cells; the cycle is longer, suitable for long-cycle human immune reconstitution and complex combination strategy research.

Detection endpoints

Human immune reconstitution ratio, T/B/NK/myeloid cell spectrum, tumor infiltration, cytokines, human immune checkpoint expression, tumor burden, survival, and major organ pathology.

Postoperative Relapse and Minimal Residual Disease Model

Postoperative relapse and minimal residual disease models typically use MOC2-luc, MOC1-luc, HSC-3-luc, or CAL-27-luc orthotopic models as the base. Once local lesions reach a predetermined burden, partial resection, local resection, or local radiotherapy is performed, followed by continuous observation of local relapse, cervical lymph node metastasis, and lung metastasis. Alternatively, after orthotopic model treatment reaches a remission-like state, BLI relapse and residual lesions can be continuously monitored.

Model characteristics
Suitable for postoperative adjuvant therapy, post-radiotherapy residual disease, local relapse, and MRD clearance research. Technically complex and longer in cycle, but closest to perioperative, post-radiotherapy residual, and MRD research scenarios.

Modeling and dosing timelines
Establish orthotopic tumor burden first, then perform local resection, amputation, or radiotherapy, followed by withdrawal or maintenance therapy, with continuous observation of time to relapse, relapse rate, and distant metastasis. The observation period is typically 6–10 weeks or longer.

Detection endpoints

Local relapse rate, time to relapse, cervical lymph node metastasis, lung metastasis, BLI relapse, survival, and residual lesion markers.

Recommended positive controls
Postoperative adjuvant programs can set cisplatin or radiotherapy references; immune maintenance programs can set anti-PD-1 or anti-PD-L1 references.

How to Select the Right Model for Your Program？

By HPV Status

By Anatomical Site

By Drug Type

By Research Objective

By Development Pathway

HPV-negative programs: Prioritize FaDu, CAL-27, SCC-9, SCC-15, SCC-25, and Detroit 562. For programs focused on EGFR, chemotherapy, radiotherapy sensitization, MET, or TGF-β, HPV-negative models typically have higher priority.
HPV-positive programs: Prioritize UM-SCC-47, UPCI-SCC090, 93-VU-147T, or HPV-related murine models. For programs involving HPV antigens, immune response, radiosensitivity, or de-escalation therapy, establish an independent HPV-positive pathway.
HPV-stratified parallel validation: To cover the broader HNSCC population, run HPV-negative and HPV-positive models in parallel. Interpret the two datasets separately rather than pooling them into a single conclusion.

Oral SCC site: Prioritize CAL-27, SCC-9, SCC-15, SCC-25, MOC1, and MOC2. For programs focused on tongue, floor-of-mouth, or buccal mucosa local invasion, escalate to orthotopic models.
Hypopharyngeal and laryngeal site: Prioritize FaDu and Detroit 562. For programs involving radiotherapy sensitization, swallowing-related local response, or hypopharyngeal/laryngeal background, consider FaDu orthotopic or local models.
Oropharyngeal HPV-positive site: Prioritize UM-SCC-47, UPCI-SCC090, and HPV-related murine models. For HPV-positive immunotherapy or radiotherapy programs, increase the priority of HPV-positive orthotopic or immune models.

Chemotherapy and radiotherapy combination: Cisplatin, fluorouracil, taxanes, and cisplatin plus radiotherapy can be screened first in subcutaneous models, then validated in orthotopic radiotherapy combination models for local control and relapse.
EGFR-targeted agents: For cetuximab-related programs, confirm EGFR expression and select CDX or orthotopic models based on the research question. For radiotherapy sensitization or local relapse, escalate to orthotopic models.
Immune checkpoint and combination immunotherapy: Anti-PD-1, anti-PD-L1, anti-CTLA-4, STING agonists, and radiotherapy combination immunotherapy should prioritize MOC1 or MOC2 syngeneic immunocompetent models. Conventional immunodeficient CDX cannot fully assess immune effects.
ADCs, bispecifics, TCEs, and cell therapy: For ADC and bispecific programs, confirm target expression first; for TCE, CAR-T/NK, and human immune-dependent programs, further consider humanized immune models and in vitro human immune killing linkage.

Rapid tumor shrinkage and PK/PD: Prioritize subcutaneous CDX. Key endpoints include TGI, RTV, terminal tumor weight, body weight, and mechanism readouts.
Local invasion and lymphatic dissemination: Prioritize skin/mucosal orthotopic models. Key endpoints include orthotopic burden, local invasion, lymph node metastasis, local pathology, and survival.
Lung metastasis: Consider tail vein experimental lung metastasis models.
Radiotherapy sensitization and post-radiotherapy relapse: Prioritize orthotopic models or post-resection/post-radiotherapy relapse models.
Immunotherapy: Prioritize MOC1 or MOC2 syngeneic models. For human immune-dependent therapies, use humanized models.
Relapse and MRD clearance: Prioritize post-resection relapse observation in orthotopic models.

HPV-negative program pathway: Subcutaneous CDX early screening → orthotopic model validation → relapse or metastasis model for deeper evaluation.
HPV-positive program pathway: HPV-positive CDX early screening → HPV-positive orthotopic or immunocompetent model validation → humanized model confirmation.
Radiotherapy sensitization pathway: Orthotopic modeling → radiotherapy combination → residual disease monitoring → relapse follow-up.
Immunotherapy pathway: MOC1/MOC2 syngeneic subcutaneous early screening → syngeneic orthotopic model validation → humanized model confirmation when needed.
ADC / bispecific / TCE pathway: Target expression confirmation → target-positive CDX → orthotopic or relapse model confirmation → humanized model for immune effect validation.

Why Alfa Cytology?

Subsite-Driven Modeling
HNSCC models cannot be generalized by a single subcutaneous tumor. Alfa Cytology builds tailored evaluation pathways based on anatomical substites (oral cavity, oropharynx, hypopharynx, and larynx), addressing distinct mucosal environments, local invasion, and radiotherapy response characteristics.

Stratified Cell Line & Model Directory
Model selection dictates translational relevance. Alfa Cytology helps clients match appropriate systems—such as CAL-27, SCC-9, FaDu, and Detroit 562—based on anatomical origin, HPV status (HPV-positive vs. HPV-negative), and driver mutation backgrounds to prevent cross-subtype misinterpretation.

Locoregional & Lymph Node Metastasis Models
Subcutaneous CDX models are suitable for early screening but fail to capture local recurrence, mucosal barrier penetration, or regional cervical lymph node metastasis. Alfa Cytology helps clients generate high-fidelity evidence through orthotopic tongue, floor of mouth, and metastasis models.

Target Validation & Integrated Immuno-Oncology Workflows
Programs targeting EGFR, PIK3CA, TGF-β, or immune checkpoints (PD-1/PD-L1) require rigorous immune contexture verification. Alfa Cytology configures syngeneic models (such as MOC series) and integrated PK/PD workflows to evaluate TME remodeling and locoregional immunotherapy response.

Alfa Cytology is a global leader in HNSCC translational research, delivering integrated animal model solutions that span HPV stratification, anatomical site-specific orthotopic modeling, cervical lymph node metastasis, radiotherapy combination, and immune microenvironment evaluation. If you are interested in our services, please don't hesitate to contact us to learn how we can accelerate your HNSCC drug development.

Reference

Johnson DE, et al. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6(1):92.

For research use only.

Solutions

Online Inquiry

Name *

Email *

Phone *

Services Interested *

Project Description

Please note that we are not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.